JP6829077B2 - グルテン不耐症及びそれから生じる障害を治療するための組成物及び方法 - Google Patents

グルテン不耐症及びそれから生じる障害を治療するための組成物及び方法 Download PDF

Info

Publication number
JP6829077B2
JP6829077B2 JP2016573565A JP2016573565A JP6829077B2 JP 6829077 B2 JP6829077 B2 JP 6829077B2 JP 2016573565 A JP2016573565 A JP 2016573565A JP 2016573565 A JP2016573565 A JP 2016573565A JP 6829077 B2 JP6829077 B2 JP 6829077B2
Authority
JP
Japan
Prior art keywords
nepenthesin
nepenthes
neprocin
protein
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016573565A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017519763A (ja
JP2017519763A5 (enExample
Inventor
シュリーマー，デービッド
レイ，マーシャル
Original Assignee
ネプエトゥクス，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ネプエトゥクス，エルエルシー filed Critical ネプエトゥクス，エルエルシー
Publication of JP2017519763A publication Critical patent/JP2017519763A/ja
Publication of JP2017519763A5 publication Critical patent/JP2017519763A5/ja
Priority to JP2021007953A priority Critical patent/JP7369893B2/ja
Application granted granted Critical
Publication of JP6829077B2 publication Critical patent/JP6829077B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/488—Aspartic endopeptidases (3.4.23), e.g. pepsin, chymosin, renin, cathepsin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/23—Aspartic endopeptidases (3.4.23)
    • C12Y304/23012—Nepenthesin (3.4.23.12)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2016573565A 2014-06-16 2015-06-16 グルテン不耐症及びそれから生じる障害を治療するための組成物及び方法 Active JP6829077B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021007953A JP7369893B2 (ja) 2014-06-16 2021-01-21 グルテン不耐症及びそれから生じる障害を治療するための組成物及び方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462012865P 2014-06-16 2014-06-16
US62/012,865 2014-06-16
US201562118396P 2015-02-19 2015-02-19
US62/118,396 2015-02-19
PCT/CA2015/000389 WO2015192211A1 (en) 2014-06-16 2015-06-16 Compositions and methods for treating gluten intolerance and disorders arising therefrom

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021007953A Division JP7369893B2 (ja) 2014-06-16 2021-01-21 グルテン不耐症及びそれから生じる障害を治療するための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2017519763A JP2017519763A (ja) 2017-07-20
JP2017519763A5 JP2017519763A5 (enExample) 2018-07-26
JP6829077B2 true JP6829077B2 (ja) 2021-02-10

Family

ID=54934596

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016573565A Active JP6829077B2 (ja) 2014-06-16 2015-06-16 グルテン不耐症及びそれから生じる障害を治療するための組成物及び方法
JP2021007953A Active JP7369893B2 (ja) 2014-06-16 2021-01-21 グルテン不耐症及びそれから生じる障害を治療するための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021007953A Active JP7369893B2 (ja) 2014-06-16 2021-01-21 グルテン不耐症及びそれから生じる障害を治療するための組成物及び方法

Country Status (8)

Country Link
US (3) US20160022785A1 (enExample)
EP (2) EP3943104A1 (enExample)
JP (2) JP6829077B2 (enExample)
CN (2) CN113827708A (enExample)
DK (1) DK3220946T3 (enExample)
ES (1) ES2883347T3 (enExample)
SI (1) SI3220946T1 (enExample)
WO (1) WO2015192211A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160022785A1 (en) 2014-06-16 2016-01-28 Nepetx, Llc Compositions and methods for treating gluten intolerance and disorders arising therefrom
JP2019504011A (ja) 2015-12-16 2019-02-14 ネプエトゥクス，エルエルシー グルテン不耐症およびそれにより発生する障害を治療するための組成物および方法
CN108504615B (zh) * 2018-03-30 2020-12-29 江南大学 一种产酸性蛋白酶的重组菌及其应用
EP4522200A2 (en) * 2022-05-10 2025-03-19 Codexis, Inc. Recombinant neprosin polypeptides and methods of expression
CN115336666A (zh) * 2022-07-05 2022-11-15 熊子奕 猪笼草捕虫囊蛋白酶降低乳清蛋白致敏性的应用及方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK81193D0 (da) 1993-07-06 1993-07-06 Novo Nordisk As Enzym
JP3767831B2 (ja) 1995-06-14 2006-04-19 木村 健 ヘリコバクター・ピロリ除菌用組成物
JPH1149697A (ja) 1997-08-01 1999-02-23 Nisshin Flour Milling Co Ltd ストレス抑制剤及びストレス抑制用食品
DE19980245D2 (de) 1998-02-23 2001-05-10 Keller Helmut Verwendung eines Preßsaftes, Verdauungssaftes oder Extraktes von fleischfressenden Pflanzen zur Hemmung von Proteinkinasen
FI980410A0 (fi) 1998-02-23 1998-02-23 Tapio Raivio Termoset
US7169175B2 (en) 2000-05-22 2007-01-30 Orbusneich Medical, Inc. Self-expanding stent
ATE505201T1 (de) 2002-02-14 2011-04-15 Univ Leland Stanford Junior Enzymbehandlung von nahrungsmitteln für zöliakie- sprue
US7320788B2 (en) * 2002-02-14 2008-01-22 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for Celiac Sprue
US8143210B2 (en) 2002-02-14 2012-03-27 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
JP4415244B2 (ja) 2003-02-21 2010-02-17 グリコ栄養食品株式会社 小麦蛋白質にプロテアーゼを限定的に作用させて得られる食品素材
US7122035B2 (en) 2003-11-13 2006-10-17 Jerome Canady Bipolar surgical forceps with argon plasma coagulation capability
CN100384442C (zh) * 2004-01-13 2008-04-30 吴琼汉 一种中草药制剂及其制备方法和应用
US7628985B2 (en) 2004-04-26 2009-12-08 The Board Of Regents Of The Leland Stanford Junior University Therapeutic enzyme formulations and uses thereof in celiac sprue and/or dermatitis herpetoformis
US20060095096A1 (en) 2004-09-09 2006-05-04 Debenedictis Leonard C Interchangeable tips for medical laser treatments and methods for using same
EP1856291A4 (en) 2005-03-04 2009-04-01 Verenium Corp NUCLEIC ACIDS AND PROTEINS, AND METHODS OF MAKING AND USING SAME
EP1949093A2 (en) 2005-10-11 2008-07-30 Alvine Pharmaceuticals, Inc. Compositions and methods for enhanced gastrointestinal stability of oligopeptides and polypeptides
AU2007299219A1 (en) 2006-04-05 2008-03-27 Metanomics Gmbh Process for the production of a fine chemical
US20080115411A1 (en) 2006-11-16 2008-05-22 Ramsey Philip W Weed control system
US7645977B2 (en) 2006-11-17 2010-01-12 New Visual Media Group, L.L.C. Low cost dynamic insulated glazing unit
CN101627098B (zh) 2006-12-04 2013-04-24 三菱瓦斯化学株式会社 含有甲醛系聚合物的树脂材料的粘接方法以及结构体
WO2008115428A2 (en) 2007-03-16 2008-09-25 The Board Of Trustees Of The Leland Stanford Junior University A scaleable manufacturing process for cysteine endoprotease b, isoform 2
EP2136833B1 (en) 2007-03-16 2019-05-01 The Board of Trustees of the Leland Stanford Junior University Combination enzyme therapy for digestion of dietary gluten
EP2229404A4 (en) 2007-12-10 2011-03-09 Univ Leland Stanford Junior ENZYMATIC POLYTHERAPY FOR GASTRIC DIGESTION OF FOOD GLUTEN IN PATIENTS WITH CELIAC DISEASE
EP2100900A1 (en) 2008-03-07 2009-09-16 Universitätsspital Basel Bombesin analog peptide antagonist conjugates
AU2009283157B2 (en) 2008-08-21 2015-02-26 Alvine Pharmaceuticals, Inc. Formulation for oral administration of proteins
EP2344183B1 (en) 2008-10-10 2015-02-25 Alvine Pharmaceuticals, Inc. Dosage forms that facilitate rapid activation of zymogen
CN101732504A (zh) * 2010-01-06 2010-06-16 宋晓翠 猪笼草和艾蒿、香蒲草制成的妇科药物及其制备方法
EP2531521B1 (en) 2010-02-02 2017-09-06 Amano Enzyme USA., Ltd. Use of proteases for gluten intolerance
EP2555792A4 (en) 2010-03-30 2013-11-06 Alvine Pharmaceuticals Inc PROTEASES DEGRADING GLUTEN
US9598684B2 (en) 2010-07-07 2017-03-21 Trustees Of Boston University Rothia species gluten-degrading enzymes and uses thereof
US9023345B2 (en) 2011-03-01 2015-05-05 Novus International, Inc. Methods for improving gut health
WO2012145369A1 (en) * 2011-04-22 2012-10-26 Faerstein Paul Joseph Compositions and methods for nutritional supplementation
US9005610B2 (en) 2012-11-21 2015-04-14 Nepetx, Llc Treatment of gluten intolerance and related conditions
US8837173B2 (en) 2013-01-02 2014-09-16 Chicony Power Technology Co., Ltd DC to DC power converting device
WO2014116871A1 (en) 2013-01-23 2014-07-31 Alvine Pharmaceuticals, Inc. Methods and pharmaceutical compositions for treating celiac disease and gluten intolerance
US20160022785A1 (en) 2014-06-16 2016-01-28 Nepetx, Llc Compositions and methods for treating gluten intolerance and disorders arising therefrom
JP2019504011A (ja) 2015-12-16 2019-02-14 ネプエトゥクス，エルエルシー グルテン不耐症およびそれにより発生する障害を治療するための組成物および方法

Also Published As

Publication number Publication date
DK3220946T3 (da) 2021-08-02
EP3220946A1 (en) 2017-09-27
JP7369893B2 (ja) 2023-10-27
US10960059B2 (en) 2021-03-30
SI3220946T1 (sl) 2021-11-30
JP2017519763A (ja) 2017-07-20
EP3943104A1 (en) 2022-01-26
US20210220451A1 (en) 2021-07-22
EP3220946A4 (en) 2018-08-15
WO2015192211A1 (en) 2015-12-23
CN106794228B (zh) 2021-09-03
US20160022785A1 (en) 2016-01-28
US20190022194A1 (en) 2019-01-24
ES2883347T3 (es) 2021-12-07
WO2015192211A9 (en) 2016-02-25
CN106794228A (zh) 2017-05-31
CN113827708A (zh) 2021-12-24
EP3220946B1 (en) 2021-06-09
US11723960B2 (en) 2023-08-15
JP2021073236A (ja) 2021-05-13

Similar Documents

Publication Publication Date Title
JP7369893B2 (ja) グルテン不耐症及びそれから生じる障害を治療するための組成物及び方法
RU2370279C2 (ru) Применение пролинспецифичных эндопротеаз для гидролиза пептидов и белков
US9598684B2 (en) Rothia species gluten-degrading enzymes and uses thereof
JP2012092125A (ja) 食品中のグルテンを低下させるためのプロテアーゼ混合物
JP6412876B2 (ja) グルテン不耐症および関連する状態の治療
US11701411B2 (en) Compositions and methods for treating gluten intolerance and disorders arising therefrom
CN1331250A (zh) 对幽门螺杆菌定居具有抑制活性的糖蛋白
JP6862627B2 (ja) 自然免疫応答疾患を治療するための医薬および方法
JP6502269B2 (ja) グルテン不耐症および関連する状態の治療
CN102365112A (zh) 治疗谷蛋白不耐受的组合物及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180614

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180614

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190702

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190910

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200310

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200608

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201013

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201027

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201208

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201222

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210121

R150 Certificate of patent or registration of utility model

Ref document number: 6829077

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250